Antibacterial Activity of Tamarindus indica Fruit Extracts against Staphylococcus aureus and Escherichia coli

Moses Phiri, Webrod Mufwambi, Steward Mudenda* and Michelo Banda

Department of Pharmacy, School of Health Sciences, The University of Zambia, P.0 Box 50110, Lusaka, Zambia

Abstract
Staphylococcus aureus and Escherichia coli cause a multitude of mild to serious infections in humans. Microorganisms such as Staphylococcus aureus and Escherichia coli have either developed resistance against the current treatments, or the current treatments cause unacceptable side effects. It is therefore imperative that research into new potential treatments is prioritized. Plants have shown to be a promising source of antibacterial agents. This study, therefore, aimed to determine the antibacterial activity of aqueous and ethanolic extracts of Tamarindus indica against Staphylococcus aureus and Escherichia coli. This was an in-vitro laboratory-based experimental study. Staphylococcus aureus and Escherichia coli were cultured in the laboratory. Different concentrations of aqueous and ethanolic plant extracts were tested for antibacterial activity using the disc diffusion method. The sensitivity of the tested microorganisms to aqueous and ethanolic plant extracts was shown by zones of inhibition after incubation. The aqueous and ethanolic extracts of Tamarindus indica exhibited activity against S. aureus and E. coli in a dose-dependent manner. The minimum inhibitory concentration was found to be 0.5 mg/ml against both micro-organisms. E. coli was more susceptible to both T. indica extracts with the 100 mg/ml dose giving a zone of inhibition of 14.8 mm ± 0.3 with the aqueous extract, and 13.5 mm ± 0.5 with the ethanolic extract. Testing of 100 mg/ml aqueous and ethanolic T. indica extracts against S. aureus resulted in maximum zones of inhibition of 8.5 mm ± 0.5. Tamarindus indica possesses dose-dependent antibacterial activity against Escherichia coli and Staphylococcus aureus.

Keywords: Antibacterial activity; Escherichia coli; Staphylococcus aureus; Tamarindus indica

Introduction
Staphylococcus aureus (S. aureus) is a gram positive pathogen that exists as normal flora on the skin, but has the ability to cause a range of conditions from minor skin and soft tissue infections to life threatening diseases such as infective endocarditis, toxic shock syndrome and osteomyelitis [1]. It is the major cause of hospitalizations at 18.8% with Escherichia coli (E. coli) following closely behind at 17.2% [2]. In the year 2017, over 119,000 S. aureus blood infections were reported in the United States with nearly 20,000 deaths occurring as a result [3]. In Zambia, a study carried out at the University Teaching Hospital, the country’s largest referral centre reported that S. aureus was isolated in 30% of burns and 34% of bloodstream infections [4].
E. coli are gram negative pathogens which exist normally in the gut [5]. It is the leading cause of Urinary Tract Infections and has also been implicated as the one of the causative organisms of pelvic inflammatory disease, pneumonia, neonatal meningitis and diarrhoea [5]. E. coli made up 18% of the stool samples positive for bacterial pathogens belonging to children aged 0-59 months that were brought to the University Teaching Hospital in Zambia between December 2015 and April 2016 [6].

Several treatments are available for these two microorganisms; S. aureus infections can be treated by several classes of drugs that include, but are not limited to, beta lactams, sulphonamides, tetracyclines, glycopeptides [7] whilst E. coli treatment includes cephalosporins and fluoroquinolones [8]. Lately, however, there has been a rise in the resistance of S. aureus and E. coli to drugs [6,9]. In Zambia, particularly at the University Teaching Hospital, the prevalence of Methicillin Resistant Staphylococcus aureus amongst S. aureus isolates rose from 23% in 2003 to 47% in 2014 [9]. Resistance of diarrhoeagenic E coli to multiple drugs was also observed at the same hospital in a separate study [6]. In addition to antibiotic resistance being a global health problem, antibiotics also possess inherent side effects [10]. For instance, fluoroquinolones have a rare tendency to cause aortic aneurysm rupture and dissection, tendon rupture, tendonitis, amongst other events, as reported by the United States Food and Drug Administration [10].

Injudicious use of antibiotics has led to antimicrobial resistance [11], and penicillins, cephalosporins that are used to treat these bacteria have been reported to cause severe adverse reactions [12]. These two factors are just some of the reasons that have necessitated the discovery of new classes of drugs [13,14]. The newer drugs must be effective against these microorganisms and also exhibit fewer side effects. People in both developed and developing countries have turned to herbal medicines as they are more natural, effective, and possess fewer side effects, which has consequently increased their demand [15]. Herbal medicines have proven effective for several conditions ranging from non-communicable diseases such as diabetes [16] to infectious diseases such as those caused by Staphylococcus aureus [17].

Tamarindus indica Linn (T. indica L.), of the Leguminosae family, is a medium sized tree located in Africa, India, the Caribbean and South America all the way up to Southern Florida [18]. It has many traditional uses in several countries and has been recorded by the British and American pharmacopoeias for its anti-pyretic, antiscorbutic, and laxative properties [18]. African slaves in Latin America used and influenced the use of T. indica in that region against infectious diseases most of which were intestinal conditions [19]. In Zambia, T. indica is used in conditions such as stomach disorders, constipation, intestinal worms, liver and gallbladder problems, dry eyes, colds and fever and even pregnancy-related nausea [20].

The aim of this research was therefore to validate the multiple reports of the use of T. indica for its antibacterial activity, particularly targeting S. aureus and E. coli.

Materials and Methods

Materials

Escherichia coli (ATC 25922), Staphylococcus aureus (ATC 25923), bacterial culture plates, swabs, cell lines, Cloxacillin, Levofloxacin, Dimethyl sulphoxide, thermometers, sterile saline, Seed pod of Tamarindus indica L.

Sample collection and plant identification

T. indica seed pods were collected from their natural habitat in the forest of Kazungula District of the Southern Province of Zambia in the month of March 2019. These pods were taken to the University of Zambia (UNZA), School of Agriculture in the Plant Science Department for botanical identification and authentication.

Laboratory equipment and personal protective equipment (PPE)

Culturing plates, test tubes, centrifugation machine, refrigerator, bacteria collecting swabs, universal transport media, gloves, laboratory coats and gowns, shoe covers, boots, respirators, face shields, safety glasses were the equipment used in this study.

Methods

Study type and design

The study was an in-vitro experimental laboratory-based study in which T. indica seed pods were tested for antibacterial activity against E. coli and S. aureus.

Study site and period

The study was carried out at the University Teaching Hospitals (UTH) in the Food and Drugs Control Laboratory, Lusaka, Zambia, from March 2019 to July 2019.

Preparation of Tamarindus indica fruit extract
Nwodo and colleagues’ method was mimicked with slight variations: Fresh and ripe fruits of T. indica were cleaned by rinsing in distilled water to remove surface contaminants. Drying was done for 14 days after which they were ready for extraction using ethanol (96%) and distilled water. In this process, 50 g of fruit was weighed using analytical balance and placed into a beaker, and then 200 ml of ethanol (96%) was added. For the water extraction, 100 g of fruit was weighed using analytical balance and placed into a conical flask, and then 400 ml of cold distilled water was added to mimic the traditional way of extraction. The samples were kept in a safe cupboard away from the light for a total of 72 hours while agitating every 12 hours. The mixtures were then separately filtered using Buchner funnels and Whatman number one filter paper to obtain the filtrate. The filtrate was then reduced to a concentrated mass by drying using a temperature-controlled evaporator at 37°C and packed into separate airtight containers at room temperature [18].

The percentage extractive yield of the aqueous and ethanolic extract was then calculated using the following formula:

\[ \text{% extraction yield} = \frac{\text{weight of extract recovered}}{\text{starting weight of the dry sample}} \times 100 \]

**Dilution of plant extracts**

Each bioactive extract was made up to 100 mg/ml by dissolving 1 g of extract in 10 ml of cold distilled water and was serially diluted to five concentrations (50, 10, 1.0, 0.5 and 0.25 mg/ml) using a weight: volume (w/v) ratio expressions.

**Culturing, collection and preparation of the bacteria**

Clinical strains of E. coli (ATCC 25922) and S. aureus (ATCC 25923) were obtained from the Microbiology at University Teaching Hospital, Lusaka, for the experiment. E. coli and S. aureus were cultured and kept in the laboratory at conditions in a dark cupboard that allowed their growth 3 days. E. coli and S. aureus were provided the environment for their survival until the day the experiment was conducted.

**Inoculum procedure**

Direct colony suspension was used. The bacteria inoculum suspension was prepared using sterile saline and turbidity compared with 0.5 McFarland turbidity standards. The turbidity was adjusted with saline until it matched that of 0.5 McFarland turbidity standards. This was done by holding the suspension and the 0.5 McFarland turbidity standards in front of a light source against a white background with contrasting black lines.

The Muller-Hinton agar plates were used and did not have excess moisture on the agar surface before inoculation and the plates were not excessively dry (wrinkled surface indicates excessive dryness). A sterile cotton swab was dipped into the bacteria suspension. Excess inoculum was removed by passing the swab inside the bacteria suspension tube. The media was then inoculated by swabbing the agar surfaces in two directions at 90-degree angle to each surface and the third line at 45-degree angle and then it was allowed to stand for 20 minutes in order to facilitate absorption of excess inoculum before application of the test plant extracts [21].

**Disc diffusion method**

Disc diffusion method was used for testing the antibacterial activities of the plant extracts. Levofloxacin 5 µg/ml and Cloxacillin 5 µg/ml were used as positive control (standard drug), while dimethyl sulphoxide (DMSO) was used as negative control to compare the results with that of experimental plant extracts. The agar plates were prepared as sterile glass petri dishes, seeded with inocula and kept for 24 hours under anaerobic conditions. Using a sterile cotton swab, the plate surface was covered in bacteria and the dried extract was then dissolved in 1 ml of DMSO using different masses of the plant extracts.

Whatman number 1 filter paper discs of 6 mm in diameter were prepared and sterilized using autoclave machine. The discs were impregnated with the different dilutions of concentrations extracts and left for some time until the extracts diffused in them and dried. Negative control was also prepared as 1.0 ml of DMSO to plain disc and was left to dry. After drying, the extracts, DMSO and the levofloxacin discs were individually placed onto the inoculated Muller-Hinton agar medium with the help of sterile forceps carefully with adequate spacing between each other and were allowed to diffuse into the media. The plates were incubated at 37°C for 24 hours [22].

**Determination of the antibacterial activities**

The different concentrations of the aqueous and ethanolic extracts of T. indica, culture strains of Escherichia coli, Staphylococcus aureus was maintained on agar plates. The sensitivity of the tested pathogenic organisms to aqueous and ethanolic extracts was shown by zones of inhibition after incubation. The zones of inhibition were measured using a plastic ruler in mm. For each concentration of the extract, the zone
of inhibition was measured three times to minimize the error and the mean was recorded. The statistical analysis was then performed.

Data analysis

Analysis of data was done using Statistical Packaging for Social Sciences (SPSS) version 21. The activity of T. indica against the test microorganisms was measured in millimetres. Statistical significance was conducted at 95% confidence levels with a p< 0.05.

Ethical considerations

The study was undertaken after due approval of the study protocol by the University of Zambia Health Sciences Research Ethics Committee. The Protocol ID was 20190217135 and IORG of 0009227.

Table 1: Percentage yields of the Ethanolic and Aqueous extract of the Seed Pod of T. indica.

| Plant name and solvent | Initial weight of the extract in grams | Weight of the extract recovered in grams (g) | Calculation of percentage yield | Percentage of extraction yield |
|------------------------|---------------------------------------|---------------------------------------------|--------------------------------|-------------------------------|
| Tamarindus indica Linn, (Ethanol) | 50.16 g | 25.79 g | 25.79 g/50.16 g x 100 | 51.4% |
| Tamarindus indica Linn (Aqueous) | 50.97 g | 23.65 g | 23.65 g/50.16 g x 100 | 46.4% |

Table 2: Mean zones of inhibition of levofloxacin and negative controls in millimetres (mm).

| Positive Control (Levofloxacin Discs) | Positive Control (Cloxacin Discs) | Negative Control (Dimethyl Sulphoxide) |
|--------------------------------------|-----------------------------------|---------------------------------------|
| Escherichia coli                    | Staphylococcus aureus             | Escherichia coli                      |
| Staphylococcus aureus               |                                   | Staphylococcus aureus                 |
| 29.0 ± 0.50                         | 30.0 ± 0.50                       | 0.0                                   |
|                                     |                                   | 0.0                                   |

Table 3: Mean zones of inhibition of bacterial growth by T. indica L. extracts in millimetres (mm).

| Extract Concentration (mg/ml) | Extract (mm) |
|-------------------------------|--------------|
|                              | Ethanol      | Aqueous      |
|                              | (mm)         | (mm)         |
|                              | Escherichia  | Staphylococcus| Escherichia   | Staphylococcus|
|                              | coli         | aureus       | coli          | aureus        |
| 0.25                          | 0            | 0            | 0             | 0             |
| 0.5                           | 1.2 ± 0.1    | 0.50 ± 0.1   | 1.9 ± 0.6     | 0.6 ± 0.1     |
| 1                             | 4.4 ± 0.1    | 1.6 ± 0.1    | 5.0 ± 0.1     | 1.6 ± 0.1     |
| 5                             | 6.0 ± 0.1    | 2.2 ± 0.1    | 6.6 ± 0.1     | 2.3 ± 0.1     |
| 10                            | 6.5 ± 0.1    | 3.7 ± 0.1    | 7.3 ± 0.2     | 3.7 ± 0.1     |
| 50                            | 10.1 ± 0.1   | 4.1 ± 0.1    | 12.3 ± 0.3    | 4.4 ± 0.2     |
| 100                           | 13.5 ± 0.5   | 8.5 ± 0.5    | 14.8 ± 0.3    | 8.5 ± 0.5     |

Results

Percentage yields of the extract

Table 1 shows different samples of the seed pod of T. indica were weighed using an electronic top pan balance for ethanolic and aqueous extracts. The ethanolic extract had a higher percentage yield of 51.4% compared to 46.4% of the aqueous extract.

Mean zones of inhibition of the standard drugs

Cloxacin and Levofloxacin were used as positive controls and were tested against S. aureus and E. coli respectively with Cloxacinlys having a zone of inhibition at 30 mm and Levofloxacin at 29 mm (Table 2). DMSO was used as a negative control and no antibacterial activity was observed against both S. aureus and E. coli.

Mean zones of inhibition of Tamarindus indica Linn. extracts in millimetres (mm)
As can be observed from the activity, the comparator study used dried leaves to give MIC of 75 mg/ml. In fact, the comparator study also determined activity against S. aureus and E. coli using fresh leaves and found that there was no activity against E. coli and the MIC was over 150 mg/ml for S. aureus.

A study conducted in Nigeria performed phytochemical analysis on the fruit pulp and found that it possessed saponins, tannins, alkaloids and attributed antibacterial activity to the presence of these phytochemicals [24]. Another study revealed the presence of flavonoids, saponins, alkaloids and tannins [26]. It is possible that some or all of these phytochemicals could have caused antibacterial activity against the tested organisms, with the possibility of working in a synergistic manner.

**Discussion**

The objective of the study was to determine the activity of *Tamarindus indica* against *Staphylococcus aureus* and *Escherichia coli*. As can be observed from the results displayed in Table 3, *T. indica* aqueous and ethanolic extracts had activity against these microorganisms, which appeared to be dose-dependent. Another result of notice is that *E. coli* was more susceptible to *T. indica* than *S. aureus*, for both the aqueous and ethanolic extracts. The highest susceptibility was observed with *E. coli* to 100 mg/ml, the highest tested dose of aqueous extract of *T. indica*, giving a zone of inhibition of 14.8 mm. The minimum inhibitory concentration of both the aqueous and ethanolic extracts of *T. indica* against *E. coli* and *S. aureus* was found to be 0.5 mg/ml.

Similar studies have found that *T. indica* fruit extracts possess activity against *E. coli* [23,24]. Interestingly, other studies found *T. indica* fruit had activity against *E. coli* but none against *S. aureus* [25,26]. It is therefore fair to say that studies thus far have revealed differences in antimicrobial activity of *T. indica*. An explanation for the differences in the antibacterial activities between studies performed in the past as well as the current study could be the difference in phytochemicals and/or their concentrations. Previous studies have afterall demonstrated that plants grown in different environments may have varying chemical constituents with different concentrations [27,28].

There are also differences between the current study and those previously published in the Minimum Inhibitory Concentration (MIC). The present study found that the MIC for both the aqueous and ethanolic extracts of *T. indica* against both *E. coli* and *S. aureus* was 0.5 mg/ml, another study that determined that antibacterial activity found that the MIC against the same strain of the bacterial organisms was 75 mg/ml [19]. This huge difference could be explained by the different phytochemicals and/or their concentrations in the plant parts used. Whereas the current study used fruit to determine antibacterial activity, the comparator study used dried leaves to give MIC of 75 mg/ml. In fact, the comparator study also determined activity against *S. aureus* and *E. coli* using fresh leaves and found that there was no activity against *E. coli* and the MIC was over 150 mg/ml for *S. aureus*.

**Conclusion**

The current study has revealed that *T. indica* aqueous and ethanolic extract inhibit *S. aureus* and *E. coli* in a dose-dependent manner. The MIC in this study was found to be 0.5 mg/ml for both the ethanol and aqueous extract against both microorganisms. Therefore, this study supports the use of *T. indica* as an antibacterial plant. Thus, a lot of research must be conducted to help discover drugs from plant sources.

**Ethical approval**

Ethical approval was granted by the University of Zambia Health Sciences Research Ethics Committee (Protocol ID: 20190217135, IORG no: 0009227, IRB no: 00011000).

**Conflict of interest**

The authors declare no conflict of interest.

**Author contribution**

All authors contributed to proposal development, write up, data collection, data analysis, manuscript writing, editing and approved the final version of the manuscript.

**Funding**


References

1. Reddy PN, Srirama K, Dirisala VR. An update on clinical burden, diagnostic tools, and therapeutic options of *Staphylococcus aureus*. Infect Dis (Auckl). 2017; 10.

2. Raho GB, Abouni B. *Escherichia coli* and *Staphylococcus aureus* most common source of infection. The Battle against Microbial Pathogens: Basic Science, Technological Advances and Educational Programs; Méndez-Vilas, A., Ed. 2015; 637-648.

3. Centre for Disease Control. Vital signs. 2019 [cited 2019 September 20]; Available from: https://www.cdc.gov/vitalsigns/staph/index.html.

4. Lukwesa-Musyani C, Hachaambwa L, Mwansa J, et al. Antibiogram Guide Edited by Microbiology DoPa. Ministry of Health, Lusaka, Zambia. 2015: 1-9.

5. MSD Manual. *Escherichia coli* infections. 2018 [cited 2019 September 20]; Available from: https://www.msdmanuals.com/professional/infectious-diseases/gram-negative-bacilli/escherichiacoli-infections.

6. Chiyangi H, Muma JB, Malama S, et al. Identification and antimicrobial resistance patterns of bacterial enteropathogens from children aged 0–59 months at the University Teaching Hospital, Lusaka, Zambia: a prospective cross sectional study. BMC Infectious Dis 2017; 17: 117.

7. David MZ, Daum RS. Treatment of *Staphylococcus aureus* Infections. Curr Top Microbiol Immunol 2017; 409: 325-383.

8. *Escherichia coli* (E. coli) Infections Medication [database on the Internet]. 2019 [cited September 20th 2019]. Available from: https://emedicine.medscape.com/article/217485-medications.

9. Samutela MT, Kalonda A, Mwansa J, et al. Molecular characterisation of methicillin-resistant *Staphylococcus aureus* (MRSA) isolated at a large referral hospital in Zambia. Pan Afr Med J 2017; 26.

10. United States Food and Drug Administration. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. 2018 [cited 2019 September 20]; Available from: https://www.fda.gov/drugs/drugsafety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics.

11. Kalonga J, Hangoma J, Banda M, et al. Antibiotic Prescribing Patterns in Paediatric Patients at Levy Mwanawasa University Teaching Hospital in Lusaka, Zambia. Int J Pharm Pharmacol 2020; 4: 138.

12. Jung IY, Kim JJ, Lee SJ, et al. Antibiotic-Related Adverse Drug Reactions at a Tertiary Care Hospital in South Korea. BioMed Res Int 2017.

13. Zalu A, Matafwali SK, Banda M, et al. Assessment of knowledge, attitude and practices on antibiotic resistance among undergraduate medical students in the school of medicine at the University of Zambia. Int J Basic Clin Pharmacol 2020; 9: 263-270.

14. Mudenda S, Bangara FF, Sitali J, et al. Knowledge, Attitude, and Practices on Antibiotic Resistance among Pharmacists at the University Teaching Hospitals in Lusaka, Zambia. J Harmonized Res 2019; 8: 12-24.

15. Modak M, Dixit P, Londhe J, et al. Devasagayam T. Indian Herbs and Herbal Drugs Used for the Treatment of Diabetes. J Clin Biochem Nutr 2007; 40: 163-173.

16. Banda M, Nyirenda J, Muzandu K, et al. Antihyperglycemic and antihyperlipidemic effects of aqueous extracts of *Lannea edulis* in alloxaninduced diabetic rats. Front Pharmacol 2018; 9.

17. Masaiti GC, Malambo C, Hikaambo C, et al. Antibacterial properties of *ficus sycomorus* bark extract against *Staphylococcus aureus* and *Escherichia coli*. Int J Biomed Invest 2019; 2: 121.

18. Nwodo UU, Obiyeke GE, Chigor VN, et al. Assessment of *Tamarindus indica* extracts for antibacterial activity. Int J Mol Sci 2011; 12: 6385-6396.

19. Escalona-Arranz JC, Pérez-Roses R, Urdaneta-Laffitta I, et al. Antimicrobial activity of extracts from *Tamarindus indica* L. leaves. Pharmacogn Mag 2010; 6: 242-247.

20. Martin M. Kawawasha! The Globe Online Newspapers. 2018 23rd September 2018.

21. Aliyu A, Musa F, Abeku R. Antibacterial activity of fruit and bark extracts of *Tamarindus indica* against *Escherichia coli* and *Staphylococcus aureus*. Bayero J Pure Appl Sci 2017; 10: 184-187.

22. Guzeldag G. Preliminary Examination of Herbal Extracts on the Inhibition of Helicobacter Pylori. Afr J Tradit Complement Altern Med 2013; 11: 93-96.

23. Jadhav DY, Sahoo AK, Ghosh JS, et al. Phytochemical detection and in vitro evaluation of tamarind fruit pulp for potential antimicrobial activity. Int J Tropic Med 2010; 5: 68-72.

24. Abdallah MS, Muhammad A. Antibacterial activity of leaves and fruits extract of *Tamarindus indica*
against clinical isolates of *Escherichia coli* and Shigella at potiskum yobe state, Nigeria. J Anal Pharm Res 2018; 7: 606-609.

25. Gadir WSA, Mohamed F, Bakhiet AO. Antibacterial activity of *Tamarindus indica* Fruit and Piper nigrum Seed. Microbiol 2007; 2: 824-830.

26. Daniyan S, Muhammad H. Evaluation of the antimicrobial activities and phytochemical properties of extracts of *Tamaridus indica* against some diseases causing bacteria. Afr J Biotechnol 2008; 7.

27. Dong J, Ma X, Wei Q, et al. Effects of growing location on the contents of secondary metabolites in the leaves of four selected superior clones of Eucommia ulmoides. Industrial Crops Products 2011; 34: 1607-1614.

28. Liu W, Liu J, Yin D, et al. Influence of ecological factors on the production of active substances in the anti-cancer plant Sinopodophyllum hexandrum (Royle) T.S. Ying. PLoS One 2015; 10: e0122981-e.

29. Muthu SE, Nandakumar S, Rao UA. The effect of methanolic extract of *Tamarindus indica* Linn. on the growth of clinical isolates of Burkholderia pseudomallei. Indian J Med Res 2005; 122: 525-528.

*This manuscript was peer-reviewed*

*Mode of Review: Single-blinded*

*Academic Editor: Dr. MA Jahangir*